Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price ...

doi:10.5334/gh.1288 2. Emmons-Bell S, et al. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108:1351-1360 3. Roger VL, et al; on behalf of the American Heart ...

SGLT2 inhibitors and mitochondrial antioxidants reversed this effect. While the study is incomplete and preliminary, its strength lies in introducing hiPSC-CMs as a tool for investigating HFpEF ...

It also backs its platform with a Happiness Guarantee. As a new homeowner, I didn't know where to go to compare prices and reviews and get honest information, but so far, HomeAdvisor has been the ...

The trial was done in adults with obesity and heart failure with preserved ejection fraction (HFpEF). The data, posted online on August 1, has not yet been published in a peer-reviewed journal.

A new review of the best available evidence has found that the rate of buprenorphine-precipitated withdrawal in adults with opioid use disorder is low and should not be a barrier to use.

Barry R. Bryant, MD, from Johns Hopkins University in Baltimore, and colleagues conducted a systematic literature review and meta-analysis to identify studies examining the efficacy and moderators ...

A PDUFA target action date of May 22, 2025 has been assigned to the application. The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Two researchers from the Icahn School of Medicine at Mount Sinai recently published their critical evaluation of a new brain tumor medicine in the journal Nature Reviews Clinical Oncology.

following a linguistic review process by the EMA. As communicated earlier this year, Novo Nordisk will resubmit to the FDA in 2025 to include data from the STEP HFpEF trials in the Wegovy label in ...

Novo Nordisk anticipates that the EU label update will take effect soon following the EMA’s linguistic review process. Novo Nordisk Development head and executive vice-president Martin Holst Lange ...